Tag: Herpes Zoster (Shingles)
Herpes Zoster Ophthalmicus Cases Increased in 2004 to 2012
Highest rates of HZO seen in older adults, women, and in whites versus other racial groups
Recombinant Zoster Vaccine Cost-Effective in Simulation
Incremental cost-effectiveness ratio varied from $10,000 to $47,000 per QALY for RZV versus no vaccine
CDC Examines Safety of Recombinant Zoster Vaccine
Total of 4,381 reports of adverse events during first eight months of use; 3 percent were serious
Risk for Zoster Up Before Dx, During Tx of Hematologic Cancer
For solid organ cancers, the risk is greater among those receiving chemotherapy
Herpes Zoster Recombinant Vaccine Seems Most Effective
However, adjuvant recombinant subunit vaccine tied to more injection site adverse events
Robust Immune Responses for Herpes Zoster Subunit Vaccine
Humoral response seen for 97.8 percent of HZ/su vaccine recipients versus 2 percent of placebo
Adjuvanted Shingles Subunit Vaccine Likely More Cost-Effective
Less overall cost and more effective than live attenuated vaccine at all ages; generally a good value
Herpes Zoster May Increase Risk of Myocardial Infarction, Stroke
More research is needed, but doctors should warn patients, researcher says
2006 to 2013 Saw Increase in ER Use for Herpes Zoster
Increase in number of emergency department visits and costs for HZ-related ER visits
Zoster Ups Stroke Risk in Patients With Autoimmune Disease
For patients with autoimmune disease, herpes zoster tied to increased stroke risk in first 90 days
